logo

BSX

Boston Scientific·NYSE
--
--(--)
--
--(--)
9.15 / 10
Outperform

The security demonstrates excellent fundamental health (9.2/10). Positive indicators: Profit-MV and Net income-Revenue, whereas limitations surface in Revenue-MV and Net profit / Total profit (%). Analytical conclusion: excellent.

Fundamental(9.15)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.67
Score0/3
Weight-18.25%
1M Return-3.20%
Annualized return on equity (%)
Value13.31
Score3/3
Weight13.49%
1M Return1.92%
Net cash flow from operating activities / Operating revenue (%)
Value-1444.83
Score3/3
Weight13.81%
1M Return1.92%
Profit-MV
Value-0.00
Score3/3
Weight27.24%
1M Return3.80%
Net income-Revenue
Value0.42
Score2/3
Weight28.00%
1M Return3.71%
ROE (diluted) (%)
Value-23.33
Score3/3
Weight13.10%
1M Return1.88%
Asset-MV
Value-0.50
Score1/3
Weight-4.15%
1M Return-0.76%
ROE (%)
Value13.31
Score3/3
Weight13.49%
1M Return1.92%
Cash-MV
Value-0.46
Score3/3
Weight27.64%
1M Return3.66%
Net profit / Total profit (%)
Value85.46
Score1/3
Weight-14.37%
1M Return-2.78%
Is BSX undervalued or overvalued?
  • BSX scores 9.15/10 on fundamentals and holds a Discounted valuation at present. Backed by its 0.00% ROE, 14.41% net margin, 39.03 P/E ratio, 4.79 P/B ratio, and 55.56% earnings growth, these metrics solidify its Outperform investment rating.